Next Article in Journal
The 3rd Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake
Previous Article in Journal
Single versus Multiple Fractions of Palliative Radiotherapy for Bone Metastases: A Randomized Clinical Trial in Iranian Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 15
Issue 3
10.3747/co.v15i3.233
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Drug-Induced Immune Thrombocytopenic Purpura Secondary to Sunitinib

by
M. Trinkaus
1,
M. Trudeau
1 and
J. Callum
2,*
1
Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada
2
Department of Hematology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2008, 15(3), 152-154; https://doi.org/10.3747/co.v15i3.233
Submission received: 6 March 2008 / Revised: 6 April 2008 / Accepted: 8 May 2008 / Published: 1 June 2008

Abstract

Sunitinib (Sutent: Pfizer, New York, NY, U.S.A.) is an oral multi-targeted tyrosine kinase inhibitor approved for use in various solid tumour malignancies. Many side effects secondary to sunitinib have been documented. In particular, sunitinib administration is known to result in thrombocytopenia, with the cause being attributed to myelosuppression. Here, we present the first case report to demonstrate immune-mediated thrombocytopenia secondary to sunitinib administration.
Keywords: breast cancer; thrombocytopenia; sunitinib breast cancer; thrombocytopenia; sunitinib

Share and Cite

MDPI and ACS Style

Trinkaus, M.; Trudeau, M.; Callum, J. Drug-Induced Immune Thrombocytopenic Purpura Secondary to Sunitinib. Curr. Oncol. 2008, 15, 152-154. https://doi.org/10.3747/co.v15i3.233

AMA Style

Trinkaus M, Trudeau M, Callum J. Drug-Induced Immune Thrombocytopenic Purpura Secondary to Sunitinib. Current Oncology. 2008; 15(3):152-154. https://doi.org/10.3747/co.v15i3.233

Chicago/Turabian Style

Trinkaus, M., M. Trudeau, and J. Callum. 2008. "Drug-Induced Immune Thrombocytopenic Purpura Secondary to Sunitinib" Current Oncology 15, no. 3: 152-154. https://doi.org/10.3747/co.v15i3.233

APA Style

Trinkaus, M., Trudeau, M., & Callum, J. (2008). Drug-Induced Immune Thrombocytopenic Purpura Secondary to Sunitinib. Current Oncology, 15(3), 152-154. https://doi.org/10.3747/co.v15i3.233

Article Metrics

Back to TopTop